XENETIC BIOSCIENCES, INC. Retained Earnings
XENETIC BIOSCIENCES, INC. (XBIO) had Retained Earnings of -$201.26 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$201.26M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$200.33M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$199.88M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$199.30M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$201.26M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$200.33M 10-Q · filed 2026-05-12 |
| 2025-12-31 | -$199.88M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$199.30M 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$198.79M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$198.10M 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$197.19M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$196.14M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$195.70M 10-Q · filed 2024-08-13 |
| 2024-03-31 | -$194.43M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$193.23M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$192.06M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$191.01M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$189.96M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$189.10M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$187.62M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$186.81M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$184.14M 10-Q · filed 2022-05-12 |
| 2021-12-31 | -$182.55M 10-K · filed 2023-03-22 |
| 2021-09-30 | -$180.71M 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$179.35M 10-Q · filed 2021-08-12 |
| 2021-03-31 | -$178.25M 10-Q · filed 2021-05-11 |
| 2020-12-31 | -$176.90M 10-K · filed 2022-03-22 |
| 2020-09-30 | -$175.70M 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$168.14M 10-Q · filed 2020-08-12 |
| 2020-03-31 | -$167.19M 10-Q · filed 2020-05-14 |
| 2019-12-31 | -$166.01M 10-K · filed 2021-03-16 |
| 2019-09-30 | -$164.84M 10-Q · filed 2019-11-14 |
| 2019-06-30 | -$155.94M 10-Q · filed 2019-08-14 |
| 2019-03-31 | -$154.56M 10-Q · filed 2019-05-13 |
| 2018-12-31 | -$153.23M 10-K · filed 2020-03-26 |
| 2018-09-30 | -$151.59M 10-Q · filed 2018-11-09 |
| 2018-06-30 | -$149.78M 10-Q · filed 2018-08-10 |
| 2018-03-31 | -$147.76M 10-Q · filed 2018-05-15 |
| 2017-12-31 | -$145.93M 10-K · filed 2019-03-29 |
| 2017-09-30 | -$150.38M 10-Q · filed 2017-11-14 |
| 2017-06-30 | -$148.12M 10-Q · filed 2017-08-14 |
| 2017-03-31 | -$145.20M 10-Q · filed 2017-05-15 |
| 2016-12-31 | -$142.34M 10-K · filed 2018-03-30 |
| 2016-09-30 | -$141.95M 10-Q · filed 2016-11-14 |
| 2016-06-30 | -$139.47M 10-Q · filed 2016-08-15 |
| 2016-03-31 | -$91.70M 10-Q · filed 2016-05-16 |
| 2015-12-31 | -$88.13M 10-K · filed 2017-03-31 |
| 2015-09-30 | -$84.50M 10-Q · filed 2015-11-16 |
| 2015-06-30 | -$79.18M 10-Q · filed 2015-08-19 |
| 2015-03-31 | -$78.06M 10-Q · filed 2015-05-20 |
| 2014-12-31 | -$75.62M 10-K · filed 2016-03-30 |
| 2014-09-30 | -$71.32M 10-Q · filed 2014-11-14 |
| 2014-06-30 | -$68.14M 10-Q · filed 2014-08-14 |
| 2014-03-31 | -$65.38M 10-Q · filed 2014-05-20 |
| 2013-12-31 | -$58.31M 10-K · filed 2015-07-20 |
| 2013-11-30 | -$399.54K 10-Q · filed 2014-01-10 |
| 2013-08-31 | -$317.08K 10-Q · filed 2014-01-10 |
| 2012-12-31 | -$49.73M 10-K · filed 2015-07-20 |
| 2012-08-31 | -$227.91K 10-K · filed 2013-11-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |